Olema Pharmaceuticals Inc
olema.comWhat Do They Do?
Develops targeted therapies for breast cancer and other cancers.
10-K for FY2025, filed Mar 16, 2026Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation…View ↗
Our lead product candidate, palazestrant (formerly known as OP-1250), is a novel, orally-available small molecule with dual activity as…View ↗
Our second product candidate in clinical development, called OP-3136, is a novel, orally-available small molecule that potently and…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 16, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$63.2MView ↗
- ▲ +44% (Loss)
- vs −$43.8M in Q2 FY2025
-
Aug 13, 2026
Appointed Jason O’Byrne as chief financial officer
Sources
8-K, filed Aug 13, 2026
On August 13, 2026, Olema Pharmaceuticals, Inc. (the “Company”) announced the appointment of Jason O’Byrne as the Company’s Chief Financial…View ↗
-
May 26, 2026
Agreed with Bayer to test OP-3136 with darolutamide
Bayer will supply darolutamide for a combination study; Olema retains global commercial and marketing rights to OP-3136.
Sources
8-K, filed May 26, 2026
As described above, on May 26, 2026, the Company announced that it had entered into the Agreement with Bayer. Pursuant to the Agreement…View ↗
Broader cancer scope The older report framed the company around women’s cancers; the latest describes targeted therapies for breast cancer and beyond.
Expanded drug pipeline The older report focused on its estrogen-receptor treatment; the latest also describes a cancer drug aimed at a different target in clinical development.
Loading...
